Mankind Pharma Ltd Falls 3.08% Amid Volatile Week: 7 Key Market Signals

2 February 2026: Stock Hits 52-Week Low Amid Continued Downtrend

Mankind Pharma’s shares declined sharply to a fresh 52-week low of Rs.2,053 on 2 February, closing at Rs.2,067.10, down 2.72% for the day. This marked a continuation of the stock’s bearish momentum, with the price trading below all key moving averages. Despite the broader market’s recovery, with the Sensex rising 1.03%, the stock underperformed, reflecting company-specific challenges including rising interest expenses and declining profitability. The stock’s one-year return stood at -16.54%, contrasting with the Sensex’s 4.48% gain, underscoring sustained underperformance.

3 February 2026: Intraday High and Open Interest Surge Signal Volatility

The stock rebounded strongly on 3 February, surging 4.30% to close at Rs.2,155.90, with an intraday high of Rs.2,152.5. This represented a notable recovery from the prior day’s lows and outperformed both the Pharmaceuticals & Biotechnology sector (+2.87%) and the Sensex (+2.63%). The price closed above its 5-day moving average, signalling short-term positive momentum, though it remained below longer-term averages.

Simultaneously, derivatives activity intensified with a 26.3% surge in open interest, rising from 12,857 to 16,237 contracts. The total derivatives value reached approximately ₹18,268 lakhs, reflecting heightened speculative and hedging activity. Despite the strong intraday gains, delivery volumes declined, suggesting that the rally was driven more by short-term trading than long-term conviction.

4 February 2026: Price Pressure Returns with Intraday Low and Elevated Volatility

On 4 February, Mankind Pharma’s stock opened higher at Rs.2,202.7 but reversed sharply to hit an intraday low of Rs.2,081, closing down 3.17% at Rs.2,089.70. The stock underperformed its sector by 3.61% and the Sensex, which was marginally down 0.08%. Technical indicators remained bearish, with the stock trading below all major moving averages and close to its 52-week low.

Derivatives open interest surged again by 27.8% to 22,188 contracts amid the price decline, suggesting increased short positioning or hedging activity. The total derivatives turnover neared ₹24,291 lakhs, with a significant notional value in options trading. Elevated intraday volatility of 5.16% reflected uncertainty and active repositioning by market participants.

5 February 2026: Continued Downtrend with Modest Losses

The stock continued its downward trajectory on 5 February, closing at Rs.2,082.55, down 0.34%. Trading volumes were moderate, and the stock remained below all key moving averages. The broader market was weaker, with the Sensex falling 0.53%. The persistent weakness highlighted ongoing investor caution amid mixed financial results and valuation concerns.

6 February 2026: New 52-Week Low Caps Off the Week

Mankind Pharma’s stock fell to a fresh 52-week low of Rs.2,029.35 intraday on 6 February, closing at Rs.2,059.55, down 1.10% for the day and 3.08% for the week. This marked a continuation of the bearish trend, with the stock trading below all major moving averages and underperforming the Pharmaceuticals & Biotechnology sector and the Sensex. The Sensex closed marginally lower by 0.10%, maintaining a positive medium-term trend, contrasting with Mankind Pharma’s weak technical positioning.

Financially, the company’s return on capital employed (ROCE) remained modest at 12.33% for the half year, down from historical levels of 25.78%. Profitability pressures and valuation concerns persist, with the enterprise value to capital employed ratio at 4.4 times. Institutional ownership remains significant at 24.59%, providing some stability amid volatility.

Daily Price Comparison: Mankind Pharma Ltd vs Sensex

Key Takeaways

Volatility and Mixed Technical Signals: The week saw sharp intraday swings with the stock hitting new 52-week lows twice, offset by a strong rebound on 3 February. Despite short-term rallies, the stock remains below all major moving averages, indicating sustained bearish momentum.

Derivatives Market Activity: Significant surges in open interest and volume in the derivatives segment suggest active repositioning by traders, with indications of both speculative buying and increased bearish hedging amid uncertain fundamentals.

Financial and Valuation Concerns: The company’s profitability has contracted, with PAT declining and interest expenses rising sharply. ROCE remains modest compared to historical levels, and valuation metrics indicate a premium stance that may be weighing on the stock price.

Institutional Ownership and Market Grade: Institutional investors hold a substantial 24.59% stake, providing some stability. However, the Mojo Score remains low at 38.0 with a Sell grade, reflecting cautious market sentiment.

Underperformance vs Sensex: The stock declined 3.08% over the week while the Sensex gained 1.51%, highlighting relative weakness and sector-specific challenges within the Pharmaceuticals & Biotechnology space.

Conclusion

Mankind Pharma Ltd’s share price performance during the week of 2–6 February 2026 was characterised by heightened volatility, fresh 52-week lows, and mixed technical signals. Despite a brief intraday rally on 3 February, the stock closed the week lower, underperforming the broader market. The surge in derivatives open interest and volume points to active repositioning and increased uncertainty among traders. Financial metrics reveal margin pressures and valuation concerns, while institutional ownership remains a stabilising factor. Overall, the stock’s current trajectory suggests continued caution amid a challenging market environment for the company.

Unlock special upgrade rates for a limited period. Start Saving Now →